Scientific deep-dive
Which GLP-1 Has the Worst Side Effects?
A network meta-analysis of 33,354 people ranks the drugs symptom by symptom. Orforglipron, the oral pill, tops the nausea ranking, ahead of every injection.
Every GLP-1 causes gastrointestinal side effects, and until recently there was no way to compare them properly. A network meta-analysis of 33,354 adults with overweight or obesity and without diabetes now ranks them. The drug with the highest nausea risk is the one people assume will be gentlest: orforglipron, the oral pill.[1]
The rankings
| Symptom | Which drugs raised the risk | Which did not |
|---|---|---|
| Nausea | All of them. Highest orforglipron, then exenatide, tirzepatide, semaglutide, liraglutide | — |
| Vomiting | Liraglutide, orforglipron, semaglutide, tirzepatide | Cagrilintide, exenatide |
| Diarrhea | Others in the analysis | Exenatide, cagrilintide, orforglipron |
| Constipation | Semaglutide, liraglutide, tirzepatide, orforglipron (see correction below) | Cagrilintide, exenatide |
Nausea, vomiting, diarrhea and constipation were the most common gastrointestinal effects across the board, which will surprise nobody taking one. What is new is being able to say which drug is worse for which symptom.[1]
The oral pill is not the gentle option
Of every drug ranked, the tablet carried the highest risk of nausea.
Orforglipron came top for nausea and was among the drugs raising vomiting risk. That matters because it is the first approved oral non-peptide in this class and it is being marketed heavily on the convenience of a tablet (see our Foundayo article). Convenience of administration and gentleness on the gut are separate properties, and here they point in opposite directions.
In this analysis orforglipron was not associated with increased diarrhea risk. A drug can rank badly on one symptom and well on another, which is why a single “tolerability” verdict is unhelpful. Orforglipron’s label figures, symptom by symptom and dose by dose, are on Foundayo side effects.
How to use a ranking like this
- Match it to your own worst symptom. If constipation is what stopped you before, switching may not solve it: tirzepatide and the oral pill raise it too, and the constipation guide covers what helps. If vomiting is the problem, the picture is different again.
- Do not read it as a dose-matched comparison. Each drug was tested at its own doses in its own trials. A ranking of drugs is not a ranking of molecules at equivalent exposure.
- This is a non-diabetic population, deliberately. Rates and rankings differ in diabetes trials, where patients are often on other gastrointestinal-active drugs.
- Dose and side effects travel together. In this analysis higher doses carried more nausea, vomiting, diarrhea and constipation, with most of the rise at the lower doses,[1] so a ranking that ignored dose and efficacy would mislead.
Frequently Asked Questions
References
- 1.Ismaiel A, Scarlata GGM, Boitos I, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis International Journal of Obesity. 2025. PMID: 40804463.
- 2.Eli Lilly and Company FOUNDAYO (orforglipron) tablets — prescribing information (section 6.1, Table 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 3.Eli Lilly and Company ZEPBOUND (tirzepatide) injection — prescribing information (section 6.1, Table 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Compare the sellers
Related research
GLP-1s and Inflammatory Bowel Disease
The pivotal trials excluded people with IBD, so the evidence is retrospective: 13 of 14 studies. It has not linked GLP-1s to more flares, and that null result deserves careful reading.
6 min read
GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days
Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.
7 min read
What Your Doctor Cannot See
Compounded semaglutide and tirzepatide appear in 8.2% of primary care records. Surveys put real use near 23%, so most of it is invisible to the record and to everything that depends on it.
6 min read
GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.
7 min read
GLP-1 Drugs and Bone: Fracture Risk, Density and What Was Measured
Across 25 studies there was no significant increase in fracture risk and lumbar bone density improved slightly. A 117-trial network analysis of 221,364 people found no GLP-1 signal either.
6 min read
Who Loses More Weight on a GLP-1?
Across 64 randomized trials, the only subgroup difference was sex: women lost 10.9% against 6.8% for men. Age, race, ethnicity, starting BMI and starting HbA1c made no significant difference.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →